E L Matteson

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Necrotizing lymphocytic vasculitis limited to the peripheral nerves: report of six cases and review
    Jose Felix Restrepo
    Facultad de Medicina, Universidad Nacional de Colombia, Calle 45, Cra 30, Bogota, Colombia
    Int J Rheumatol 2009:368032. 2009
  2. pmc Reliability exercise for the polymyalgia rheumatica classification criteria study: the oranjewoud ultrasound substudy
    Alexander K Scheel
    Department of Nephrology and Rheumatology, Georg August University Gottingen, 37073 Gottingen, Germany
    Int J Rheumatol 2009:738931. 2009
  3. pmc Trends in lipid profiles in patients with psoriasis: a population-based analysis
    Bharath Manu Akkara Veetil
    Division of Rheumatology, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    BMC Dermatol 12:20. 2012
  4. doi request reprint Malignancy as a comorbidity in rheumatic diseases
    Carl Turesson
    Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Rheumatology (Oxford) 52:5-14. 2013
  5. doi request reprint History of vasculitis: the life and work of Adolf Kussmaul
    Eric L Matteson
    Division of Rheumatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cleve Clin J Med 79:S54-6. 2012
  6. pmc A profile of immune response to herpesvirus is associated with radiographic joint damage in rheumatoid arthritis
    John M Davis
    Division of Rheumatology, Department of Medicine, College of Medicine, Mayo Clinic 200 First Street SW, Rochester, MN 55905, USA
    Arthritis Res Ther 14:R24. 2012
  7. doi request reprint Patient-reported outcomes in polymyalgia rheumatica
    Eric L Matteson
    Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Rheumatol 39:795-803. 2012
  8. pmc 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative
    Bhaskar Dasgupta
    Department of Rheumatology, Southend University Hospital, Westcliff on Sea, Essex, UK
    Ann Rheum Dis 71:484-92. 2012
  9. pmc Orthopedic surgery among patients with rheumatoid arthritis 1980-2007: a population-based study focused on surgery rates, sex, and mortality
    Courtney A Shourt
    Department of Medicine, Division of Rheumatology, Mayo Clinic, Rochester, MN 55905, USA
    J Rheumatol 39:481-5. 2012
  10. pmc Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009
    Timothy C Olson
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    BMC Infect Dis 11:145. 2011

Research Grants

  1. Genetic Polymorphisms in Rheumatoid Arthritis
    Eric Matteson; Fiscal Year: 2004

Detail Information

Publications109 found, 100 shown here

  1. pmc Necrotizing lymphocytic vasculitis limited to the peripheral nerves: report of six cases and review
    Jose Felix Restrepo
    Facultad de Medicina, Universidad Nacional de Colombia, Calle 45, Cra 30, Bogota, Colombia
    Int J Rheumatol 2009:368032. 2009
    ....
  2. pmc Reliability exercise for the polymyalgia rheumatica classification criteria study: the oranjewoud ultrasound substudy
    Alexander K Scheel
    Department of Nephrology and Rheumatology, Georg August University Gottingen, 37073 Gottingen, Germany
    Int J Rheumatol 2009:738931. 2009
    ..US of shoulder and hips performed by different examiners is a reliable and feasible tool for assessment of PMR related disease pathology and can be incorporated into a classification criteria study...
  3. pmc Trends in lipid profiles in patients with psoriasis: a population-based analysis
    Bharath Manu Akkara Veetil
    Division of Rheumatology, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    BMC Dermatol 12:20. 2012
    ..Psoriasis is associated with an atherogenic lipid profile but longitudinal changes in lipids around disease onset are unknown. The purpose of our study is to examine the effect of psoriasis onset on serum lipid profiles...
  4. doi request reprint Malignancy as a comorbidity in rheumatic diseases
    Carl Turesson
    Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Rheumatology (Oxford) 52:5-14. 2013
    ..Effective screening and monitoring strategies are important in reducing the risk of cancer in these patients...
  5. doi request reprint History of vasculitis: the life and work of Adolf Kussmaul
    Eric L Matteson
    Division of Rheumatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cleve Clin J Med 79:S54-6. 2012
    ..A much-loved teacher and respected physician and researcher, Kussmaul's desire to understand disease, his careful clinical observations, and his innovative thinking in medical technology mark him as a pioneer in modern rheumatology...
  6. pmc A profile of immune response to herpesvirus is associated with radiographic joint damage in rheumatoid arthritis
    John M Davis
    Division of Rheumatology, Department of Medicine, College of Medicine, Mayo Clinic 200 First Street SW, Rochester, MN 55905, USA
    Arthritis Res Ther 14:R24. 2012
    ..This study was undertaken to identify profiles of immune response that correlate with radiographic joint damage as a first step toward the discovery of new pathogenic mechanisms of joint destruction in RA...
  7. doi request reprint Patient-reported outcomes in polymyalgia rheumatica
    Eric L Matteson
    Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Rheumatol 39:795-803. 2012
    ..To prospectively evaluate the disease course and the performance of clinical, patient-reported outcome (PRO) and musculoskeletal ultrasound measures in patients with polymyalgia rheumatica (PMR)...
  8. pmc 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative
    Bhaskar Dasgupta
    Department of Rheumatology, Southend University Hospital, Westcliff on Sea, Essex, UK
    Ann Rheum Dis 71:484-92. 2012
    ..These criteria are not meant for diagnostic purposes...
  9. pmc Orthopedic surgery among patients with rheumatoid arthritis 1980-2007: a population-based study focused on surgery rates, sex, and mortality
    Courtney A Shourt
    Department of Medicine, Division of Rheumatology, Mayo Clinic, Rochester, MN 55905, USA
    J Rheumatol 39:481-5. 2012
    ..To describe current trends in arthritis-related joint surgery among a population-based cohort of patients with rheumatoid arthritis (RA) and to examine the influence of joint surgery on mortality...
  10. pmc Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009
    Timothy C Olson
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    BMC Infect Dis 11:145. 2011
    ..Patients with rheumatic diseases including rheumatoid arthritis (RA) are at increased risk for infections related to both the disease and its treatments. These include uncommonly reported infections due to histoplasmosis...
  11. pmc Response to commentary by Dixon and Silman on the systematic review and meta-analysis by Bongartz et al
    Eric L Matteson
    Arthritis Res Ther 8:404. 2006
  12. pmc Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study
    Kenneth J Warrington
    Department of Medicine, Division of Rheumatology, Mayo Clinic, Rochester, MN 55905, USA
    Arthritis Res Ther 11:R50. 2009
    ..The present study was conducted to determine whether patients with polymyalgia rheumatica (PMR) are at an increased risk of peripheral arterial disease (PAD)...
  13. pmc Cardiovascular risk factors and acute-phase response in idiopathic ascending aortitis: a case control study
    Vaidehi R Chowdhary
    Division of Rheumatology, Department of Medicine, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    Arthritis Res Ther 11:R29. 2009
    ..Idiopathic aortitis is a rare condition characterized by giant cell or lymphoplasmacytic inflammation of the aorta. The purpose of this study was to describe risk factors for the development of idiopathic aortitis...
  14. pmc The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis
    Carl Turesson
    Department of Rheumatology, Malmo University Hospital, Södra Förstadsgatan 101, 205 02 Malmo, Sweden
    Arthritis Res Ther 7:R1386-93. 2005
    ..This confirms that SE genes contribute to RA disease severity and ExRA. Other genetic and environmental factors may have a more specific impact on individual ExRA manifestations...
  15. pmc Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies
    Carlotta Nannini
    Division of Rheumatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Arthritis Res Ther 10:R124. 2008
    ..The purpose of the present study was to systematically review the effect of cyclophosphamide treatment on pulmonary function in patients with systemic sclerosis and interstitial lung disease...
  16. pmc Are classification criteria for vasculitis useful in clinical practice? Observations and lessons from Colombia
    Paúl Alejandro Méndez Patarroyo
    Department of Internal Medicine, Rheumatology Unit, Universidad Nacional de Colombia, Bogota, Columbia
    J Autoimmune Dis 6:1. 2009
    ....
  17. ncbi request reprint Historical perspective of vasculitis: polyarteritis nodosa and microscopic polyangiitis
    Eric L Matteson
    Division of Rheumatology, Mayo Clinic and Foundation, 200 1st Street SE, Rochester, MN 55905, USA
    Curr Rheumatol Rep 4:67-74. 2002
    ..Historically, most forms of vasculitis described subsequently have been characterized and classified on the basis of features similar to or distinct from polyarteritis...
  18. ncbi request reprint How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial
    E L Matteson
    Division of Rheumatology, Mayo Clinic and Mayo Graduate School of Medicine, Rochester, MN 55905, USA
    Rheumatology (Oxford) 43:619-25. 2004
    ..To determine what baseline factors might be associated with response to an initial mild treatment regimen in patients with early rheumatoid arthritis (RA)...
  19. ncbi request reprint Think clearly, be sincere, act calmly: Adolf Kussmaul (February 22, 1822-May 28, 1902) and his relevance to medicine in the 21st century
    Eric L Matteson
    Division of Rheumatology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Curr Opin Rheumatol 15:29-34. 2003
    ..Kussmaul's life and career, dedicated foremost to reducing human suffering and advancing medicine as a scientific discipline with a strong humanistic foundation, make him a role model for physicians of today...
  20. ncbi request reprint Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study
    Eric L Matteson
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Arthritis Rheum 53:337-42. 2005
    ..The objective of the current study was to preliminarily evaluate the efficacy of etanercept therapy for IMCVD...
  21. ncbi request reprint Citrullination in extra-articular manifestations of rheumatoid arthritis
    T Bongartz
    Division of Rheumatology, Mayo Clinic College of Medicine, 200 1St St SW Rochester, MN 55905, USA
    Rheumatology (Oxford) 46:70-5. 2007
    ..We therefore investigated the presence of citrullination in two extra-articular manifestations of RA, interstitial pneumonia (IP) and rheumatoid nodules...
  22. ncbi request reprint Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept
    M Baghai
    Department of Surgery, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 76:653-6. 2001
    ....
  23. ncbi request reprint Open trial of methotrexate as treatment for autoimmune hearing loss
    E L Matteson
    Division of Rheumatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Arthritis Rheum 45:146-50. 2001
    ..CONCLUSION: Long-term low-dose MTX therapy may be a useful therapy for at least some patients who have hearing loss with a presumptively autoimmune-mediated component that is refractory to traditional therapies...
  24. pmc Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations
    Kimberly P Liang
    Mayo Clinic and Mayo Graduate School of Medicine, Rochester, Minnesota, USA
    Arthritis Rheum 54:642-8. 2006
    ..To investigate the incidence of noncardiac vascular disease in patients with rheumatoid arthritis (RA) and its relationship to systemic extraarticular disease in a community-based cohort...
  25. doi request reprint Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis
    Cynthia S Crowson
    Division of Rheumatology, Mayo Clinic, Rochester, MN, USA
    J Rheumatol 36:1606-10. 2009
    ..To assess clinical utility of measurements of C-reactive protein (CRP) versus Westergren erythrocyte sedimentation rate (ESR) in evaluating patients with rheumatoid arthritis (RA)...
  26. ncbi request reprint Testicular involvement in rheumatoid vasculitis
    D F Mayer
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Exp Rheumatol 22:S62-4. 2004
    ..This unusual presentation of rheumatoid vasculitis was successfully treated with a combination of corticosteroids and cyclophosphamide...
  27. doi request reprint Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study
    C Nannini
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Lupus 18:394-9. 2009
    ..MMF treatment significantly reduced the total number of lupus flares and prednisone requirements. Even with the reduction in mean daily prednisone dose, both the SLEDAI and physican global assessment also improved during MMF therapy...
  28. doi request reprint Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials
    T Bongartz
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Ann Rheum Dis 68:1177-83. 2009
    ..To assess the risk of malignancy with etanercept, a fusion protein that inhibits TNF action, a meta-analysis was performed using individual patient data from randomised controlled trials (RCT) in patients with rheumatoid arthritis (RA)...
  29. ncbi request reprint The utility of positron emission tomography in the evaluation of autoimmune hearing loss
    Mehrdad Mazlumzadeh
    Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA
    Otol Neurotol 24:201-4. 2003
    ..To evaluate positron emission tomography as an imaging tool in the diagnosis, evaluation, and management of autoimmune inner ear disease...
  30. ncbi request reprint Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis
    Ewa Bryl
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Arthritis Rheum 52:2996-3003. 2005
    ..Because reduced expression of CD28 in T cells compromises immunocompetence, we examined whether CD28 expression is reduced in patients with RA in vivo and whether the reduction is related to TNFalpha...
  31. pmc Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis
    Haidong Dong
    Department of Immunology, Mayo Medical School and Graduate School, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Invest 111:363-70. 2003
    ....
  32. pmc Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis
    C Turesson
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Ann Rheum Dis 66:70-5. 2007
    ..Rheumatoid arthritis is associated with increased cardiovascular mortality and morbidity...
  33. pmc Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years
    C Turesson
    Department of Rheumatology, Malmo University Hospital, Lund University, Sweden
    Ann Rheum Dis 62:722-7. 2003
    ..To investigate the trends in incidence of extra-articular rheumatoid arthritis (ExRA) in a well defined community based cohort of patients with rheumatoid arthritis (RA), and to examine possible predictors of ExRA occurrence...
  34. pmc Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis
    C Turesson
    Department of Rheumatology, Malmo University Hospital, Södra Förstadsgatan 101, S 205 02 Malmo, Sweden
    Ann Rheum Dis 66:59-64. 2007
    ..To study antibodies to cyclic citrullinated peptides (anti-CCP) and rheumatoid factor in patients with active, severe extra-articular rheumatoid arthritis (ExRA) compared with controls without ExRA...
  35. doi request reprint Biologic response modifiers for ophthalmologists
    James A Garrity
    Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ophthal Plast Reconstr Surg 24:345-7. 2008
  36. ncbi request reprint Lyme myositis
    Aaron R Holmgren
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Arthritis Rheum 54:2697-700. 2006
    ..The current case is reviewed in the context of findings from previous case descriptions...
  37. doi request reprint Vasculitis in rheumatoid arthritis
    Carl Turesson
    Department of Rheumatology, Malmo University Hospital, Malmo, Sweden
    Curr Opin Rheumatol 21:35-40. 2009
    ..To examine the occurrence and pathophysiology of vasculitis in rheumatoid arthritis (RA), describe the epidemiology and clinical features, and provide a therapeutic perspective...
  38. ncbi request reprint Is tacrolimus effective for treating antisynthetase-associated interstitial lung disease?
    Tim Bongartz
    Division of Rheumatology, Mayo Clinic, Rochester, MN 55905, USA
    Nat Clin Pract Rheumatol 1:80-1. 2005
  39. ncbi request reprint Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis
    Carl Turesson
    Department of Rheumatology, Malmo University Hospital, Malmo, Sweden
    Arthritis Rheum 54:2776-83. 2006
    ..To compare HLA-C genotypes and smoking habits in patients with vasculitis or other severe extraarticular manifestations of rheumatoid arthritis (ExRA) with those in RA patients without extraarticular disease...
  40. doi request reprint Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study
    Tim Bongartz
    Rheumatology Department, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Arthritis Rheum 62:1583-91. 2010
    ..Interstitial lung disease (ILD) has been recognized as an important comorbidity in rheumatoid arthritis (RA). We undertook the current study to assess incidence, predictors, and mortality of RA-associated ILD...
  41. ncbi request reprint Autoimmune inner ear disease: diagnostic and therapeutic approaches in a multidisciplinary setting
    Eric L Matteson
    Department of Internal Medicine, Division of Rheumatology Mayo Clinic and Mayo Graduate School of Medicine Rochester, Minnesota 55905, USA
    J Am Acad Audiol 14:225-30. 2003
    ..One of our conclusions is that many of these patients respond favorably to the treatment Methotrexate...
  42. pmc Systemic lupus erythematosus features in rheumatoid arthritis and their effect on overall mortality
    Murat Icen
    Department of Health Sciences Research, Mayo Foundation, 200 First St SW, Rochester, MN 55905, USA
    J Rheumatol 36:50-7. 2009
    ..However, their frequency and clinical significance are uncertain. We examined the frequency of SLE features in RA and their effect on overall mortality...
  43. pmc Anti-cyclic citrullinated peptide, rheumatoid factor, and ocular symptoms typical of rheumatoid arthritis
    Sujit Itty
    Mayo Medical School, Mayo Clinic, Rochester, Minnesota, USA
    Trans Am Ophthalmol Soc 106:75-81; discussion 81-3. 2008
    ..To correlate the presence of anti-cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF) with ocular symptoms typical of rheumatoid arthritis (RA)...
  44. ncbi request reprint Cardiovascular risk factors, fitness and physical activity in rheumatic diseases
    Carl Turesson
    Department of Rheumatology, Malmo University Hospital, Malmo, Sweden
    Curr Opin Rheumatol 19:190-6. 2007
    ..In this review, we highlight recent findings on risk factors for cardiovascular disease in patients with rheumatic diseases, and explore the role of physical activity for the prevention of cardiovascular disease...
  45. ncbi request reprint Primer: Demystifying risk--understanding and communicating medical risks
    Cynthia S Crowson
    Department of Health Sciences Research, all at the Mayo Clinic, Rochester, MN 55905, USA
    Nat Clin Pract Rheumatol 3:181-7; quiz 1 p following 187. 2007
    ..In the face of uncertainty, making a provisional decision with a plan to review it later can be a good strategy. Verifying the patient's comprehension can help ensure that the decisions reached are informed and acceptable...
  46. ncbi request reprint Concomitant giant cell aortitis, thoracic aortic aneurysm, and aortic arch syndrome: occurrence in a patient and significance
    Dirk M Nuenninghoff
    Mayo Clinic and Mayo Graduate School of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Arthritis Rheum 49:858-61. 2003
  47. doi request reprint Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis
    Tim Bongartz
    Mayo Clinic College of Medicine, Division of Rheumatology, Rochester, Minnesota 55905, USA
    Arthritis Rheum 59:1713-20. 2008
    ..We conducted a study to evaluate potential risk factors of prosthetic joint infection and to clarify if RA is an independent predictor of this complication...
  48. ncbi request reprint Cogan's syndrome: an audiovestibular, ocular, and systemic autoimmune disease
    Mehrdad Mazlumzadeh
    Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Rheum Dis Clin North Am 33:855-74, vii-viii. 2007
    ..A poor outcome, especially complete hearing loss, can sometimes be prevented through a timely recognition and initiation of glucocorticoid therapy at the onset of the disease...
  49. ncbi request reprint Prognostic markers of radiographic progression in early rheumatoid arthritis
    Jorg J Goronzy
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Arthritis Rheum 50:43-54. 2004
    ..To identify prognostic markers that are predictive of progressive erosive disease in patients with early rheumatoid arthritis (RA)...
  50. pmc Cardiovascular co-morbidity in rheumatic diseases
    Carl Turesson
    Department of Rheumatology, Malmo University Hospital, Malmo, Sweden
    Vasc Health Risk Manag 4:605-14. 2008
    ..In this review, the research agenda for understanding and preventing CVD co-morbidity in patients with rheumatic disorders is discussed...
  51. ncbi request reprint Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials
    Tim Bongartz
    Division of Rheumatology and Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    JAMA 295:2275-85. 2006
    ..Tumor necrosis factor (TNF) plays an important role in host defense and tumor growth control. Therefore, anti-TNF antibody therapies may increase the risk of serious infections and malignancies...
  52. ncbi request reprint Infectious complications of tumor necrosis factor-alpha antagonists
    Mohanad Bakleh
    Division of Infectious Diseases and Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Int J Dermatol 44:443-8. 2005
  53. doi request reprint Lack of association of high body mass index with risk for developing polymyalgia rheumatica
    Deana D Hoganson
    Division of Rheumatology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Rheum Dis 13:e1-5. 2010
    ..Objectives: To determine the association between BMI and polymyalgia rheumatica (PMR) as well as the influence of BMI on glucocorticoid treatment duration and development of giant-cell arteritis (GCA) in patients with PMR...
  54. pmc Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells
    John M Davis
    Division of Rheumatology, Department of Medicine, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Immunol 184:7297-304. 2010
    ..Thus, our approach lays the foundation for the development of immunologic "signatures" that could be useful in predicting disease course and monitoring the outcomes of therapy among patients with immune-mediated diseases...
  55. ncbi request reprint Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years
    Sherine E Gabriel
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Arthritis Rheum 48:54-8. 2003
    ..To evaluate trends in and risk factors for mortality among patients with rheumatoid arthritis (RA) over a 40-year period...
  56. ncbi request reprint Genetics of rheumatoid arthritis
    Carl Turesson
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 81:94-101. 2006
    ....
  57. pmc Cancer preceding giant cell arteritis: a case-control study
    Tanaz A Kermani
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Arthritis Rheum 62:1763-9. 2010
    ..To study the association between previous cancer and giant cell arteritis (GCA)...
  58. ncbi request reprint Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia
    Sarah R Atkins
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Arthritis Rheum 54:635-41. 2006
    ..We performed a morphologic and quantitative analysis of B lymphocytes and plasma cells in RA-associated interstitial pneumonia (IP) in comparison with idiopathic IP and normal lungs...
  59. pmc Malignancy risk in patients with giant cell arteritis: a population-based cohort study
    Tanaz A Kermani
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Arthritis Care Res (Hoboken) 62:149-54. 2010
    ..To determine the incidence of cancer in a population-based cohort of patients with giant cell arteritis (GCA) compared with age- and sex-matched referent subjects...
  60. ncbi request reprint Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis
    Carl Turesson
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Arthritis Rheum 52:73-9. 2005
    ..To study lymphocyte markers in rheumatoid arthritis (RA)-associated interstitial pneumonitis (IP) compared with idiopathic IP...
  61. ncbi request reprint Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab
    James A Garrity
    Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Ophthalmol 138:925-30. 2004
    ..To report results of treatment with a monoclonal antibody (infliximab) directed against tumor necrosis factor alpha in seven patients with chronic and difficult-to-control idiopathic orbital inflammation (orbital myositis)...
  62. ncbi request reprint Localized nodular vasculitis: a new variant of localized cutaneous polyarteritis nodosa?
    G Quintana
    Rheumatology Unit, School of Medicine, National University of Colombia, Bogota, Colombia
    Clin Exp Rheumatol 22:S31-4. 2004
    ....
  63. ncbi request reprint No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: results from a community-based study
    Carl Turesson
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Arthritis Rheum 50:3729-31. 2004
  64. ncbi request reprint Genetics of rheumatoid arthritis: Is there a pattern predicting extraarticular manifestations?
    Carl Turesson
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Arthritis Rheum 51:853-63. 2004
  65. doi request reprint Symptomatic lower extremity vasculitis in giant cell arteritis: a case series
    Tanaz A Kermani
    Division of Rheumatology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55901, USA
    J Rheumatol 36:2277-83. 2009
    ..To describe the clinical features and outcomes of 19 patients with giant cell arteritis (GCA) and symptomatic lower extremity (LE) vasculitis...
  66. pmc Renal involvement in primary Sjögren's syndrome: a clinicopathologic study
    Saugar Maripuri
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin J Am Soc Nephrol 4:1423-31. 2009
    ..Renal pathology and clinical outcomes in patients with primary Sjögren's syndrome (pSS) who underwent kidney biopsy (KB) because of renal impairment are reported...
  67. ncbi request reprint Interstitial lung disease in primary Sjögren syndrome
    Joseph G Parambil
    Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Chest 130:1489-95. 2006
    ..Primary Sjögren syndrome (pSS) has been associated with various histologic patterns of interstitial lung disease (ILD)...
  68. ncbi request reprint Cogan syndrome: a retrospective review of 60 patients throughout a half century
    Michael B Gluth
    Department of Otorhinolaryngology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 81:483-8. 2006
    ..To evaluate the disease manifestations and clinical course of patients affected by Cogan syndrome (a syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms) at a single institution during roughly a half century...
  69. ncbi request reprint Management of extra-articular disease manifestations in rheumatoid arthritis
    Carl Turesson
    Division of Rheumatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Curr Opin Rheumatol 16:206-11. 2004
    ..To discuss the rationale for various treatment strategies in rheumatoid arthritis with extra-articular manifestations, and to review advances in understanding the impact of extra-articular rheumatoid arthritis and its management...
  70. ncbi request reprint Recurrence of Susac syndrome (retinocochleocerebral vasculopathy) after remission of 18 years
    G W Petty
    Division of Cerebrovascular Diseases, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 76:958-60. 2001
    ..Clinicians should be aware of the possibility of late recurrence of Susac syndrome when evaluating patients with a distant history of the syndrome who present with complaints referable to the brain, retina, and cochlea...
  71. ncbi request reprint Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan
    E L Matteson
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Exp Rheumatol 27:253-9. 2009
    ..This study is a preliminary assessment of the safety and usage of a radiopharmaceutical, FolateScan (Technetium-99m EC20; 99mTc-EC20), for detecting disease activity in patients with rheumatoid arthritis...
  72. ncbi request reprint Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years
    Dirk M Nuenninghoff
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Arthritis Rheum 48:3522-31. 2003
    ..To determine the incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis (GCA)...
  73. ncbi request reprint A patient remembers the miracle drug cortisone 50 years later
    Eric L Matteson
    Division of Rheumatology, Mayo Clinic Rochester, USA
    Minn Med 85:12-5. 2002
  74. doi request reprint Lung disease in rheumatoid arthritis
    Carlotta Nannini
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Curr Opin Rheumatol 20:340-6. 2008
    ..To examine the role of lung disease in rheumatoid arthritis from a clinical, epidemiologic, pathophysiologic, and therapeutic perspective...
  75. pmc Morphological and quantitative assessment of mast cells in rheumatoid arthritis associated non-specific interstitial pneumonia and usual interstitial pneumonia
    S R Atkins
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Rheum Dis 65:677-80. 2006
    ..The role of mast cells in extra-articular manifestations of rheumatoid arthritis (RA) has not been studied so far...
  76. ncbi request reprint Management guidelines and outcome measures in giant cell arteritis (GCA)
    K J Warrington
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Exp Rheumatol 25:137-41. 2007
    ..Disease relapses and steroid-related adverse effects, however, are common. Serious complications of the disease may include visual loss, stroke, and aortic involvement with aneurysm formation...
  77. ncbi request reprint Large-vessel involvement in giant cell arteritis
    Tim Bongartz
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Curr Opin Rheumatol 18:10-7. 2006
    ..Stenosis of the primary and secondary branches of the aorta may cause claudication and tissue gangrene, whereas aortitis may lead to aneurysm formation and dissection, often many years after the initial diagnosis...
  78. ncbi request reprint The future of damage assessment in vasculitis
    Philip Seo
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Rheumatol 34:1357-71. 2007
    ..This initiative is part of a larger international effort to create a unified approach to disease assessment for the primary systemic vasculitides...
  79. ncbi request reprint Small-vessel vasculitis
    Antonio Iglesias-Gamarra
    Division of Rheumatology, Mayo Clinic College of Medicine, Southwest, Rochester, MN 55905, USA
    Curr Rheumatol Rep 9:304-11. 2007
    ....
  80. ncbi request reprint Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years
    Dirk M Nuenninghoff
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Arthritis Rheum 48:3532-7. 2003
    ..To determine the mortality of giant cell arteritis (GCA) with large-artery complication compared with that of GCA without large-artery complication...
  81. ncbi request reprint Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial
    Mehrdad Mazlumzadeh
    Mayo Clinic, Scottsdale, Arizona, USA
    Arthritis Rheum 54:3310-8. 2006
    ..The goal of the current study was to test the hypothesis that induction treatment with high-dose pulse intravenous (IV) methylprednisolone permits a shorter course of therapy...
  82. pmc Lack of detection of human retrovirus-5 proviral DNA in synovial tissue and blood specimens from individuals with rheumatoid arthritis or osteoarthritis
    Kerryl E Piper
    Division of Infectious Diseases, Dept of Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Arthritis Rheum 55:123-5. 2006
    ..The purpose of this study was to determine if human retrovirus-5 proviral DNA is present in synovial tissue and blood specimens from patients with rheumatoid arthritis or osteoarthritis, or those without joint disease...
  83. ncbi request reprint Initial contributions of Adamantiades and Behçet
    Kenneth T Calamia
    Mayo Clinic and Mayo Graduate School of Medicine, Rochester, Minnesota, USA
    Adv Exp Med Biol 528:3-5. 2003
  84. ncbi request reprint The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis
    D M Nuenninghoff
    Division of Rheumatology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Clin Exp Rheumatol 21:S29-34. 2003
    ..Thus far, no disease-modifying antirheumatic drug therapy or alternative to daily glucocorticosteroid therapy has been found to be unequivocally effective in the treatment of GCA...
  85. pmc The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases
    Hilal Maradit Kremers
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Rheumatology (Oxford) 50:6-15. 2011
    ....
  86. pmc Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study
    Elena Myasoedova
    Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Rheumatol 38:983-9. 2011
    ..To assess incidence and mortality effects of extraarticular rheumatoid arthritis (ExRA) in patients with incident RA in 1995-2007 compared to 1985-1994, in Olmsted County, Minnesota, USA...
  87. ncbi request reprint Hearing loss in rheumatoid arthritis
    Christine S Halligan
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Laryngoscope 116:2044-9. 2006
    ..The objective of this study was to evaluate whether patients with rheumatoid arthritis (RA) are more likely to have subclinical hearing loss compared with persons without RA...
  88. pmc Polymyalgia rheumatica
    Clement J Michet
    Division of Rheumatology, Mayo Clinic, Rochester, MN 55905, USA
    BMJ 336:765-9. 2008
  89. ncbi request reprint An open-label, phase I/II study of 5-fluorouracil plus leucovorin in the treatment of rheumatoid arthritis
    Thomas W Bunch
    J Rheumatol 29:1109-10. 2002
  90. ncbi request reprint Need for circumspection in prescribing tumor necrosis factor inhibitors and other biologic response modifiers
    Eric L Matteson
    Arthritis Rheum 47:1-4. 2002
  91. ncbi request reprint Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis
    Peter D Kent
    Arthritis Rheum 46:2257-8; author reply 2259. 2002
  92. ncbi request reprint Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis
    Carl Turesson
    Department of Rheumatology, Malmo University Hospital, Sweden
    J Rheumatol 29:62-7. 2002
    ..To investigate the occurrence of extraarticular manifestations (ExRA) in a well defined community based cohort of patients with rheumatoid arthritis (RA), and to examine their effect on mortality...
  93. ncbi request reprint Citrullinated proteins in rheumatoid arthritis: crucial...but not sufficient!
    Tineke Cantaert
    University of Amsterdam, Amsterdam, The Netherlands
    Arthritis Rheum 54:3381-9. 2006
  94. ncbi request reprint A population based assessment of the use of orthopedic surgery in patients with rheumatoid arthritis
    Loreto Massardo
    Department of Clinical Immunology and Rheumatology, Catholic University of Chile, Santiago
    J Rheumatol 29:52-6. 2002
    ..To describe the use of orthopedic surgery, including joint replacement surgery, in a well defined population based cohort of patients with rheumatoid arthritis (RA) and to identify characteristics that predict such use...
  95. ncbi request reprint Lupus arthropathy: historical evolution from deforming arthritis to rhupus
    Andres Fernandez
    Department of Internal Medicine, Rheumatology Unit, Universidad Nacional de Colombia, Bogota, Colombia
    Clin Rheumatol 23:523-6. 2004
    ..Instead, rhupus arthropathy should be regarded as a variant of the arthropathy of systemic lupus erythematosus...
  96. ncbi request reprint Tumor necrosis factor antagonists and infections: the small print on the price tag
    Tim Bongartz
    Arthritis Rheum 53:631-5. 2005
  97. ncbi request reprint Signs of systemic disease are strong determinants of mortality in rheumatoid arthritis: comment on the article by Navarro-Cano et al
    Carl Turesson
    Arthritis Rheum 50:1695-6; author reply 1696-7. 2004
  98. doi request reprint Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study
    Jonathan Kay
    Rheumatology Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
    Arthritis Rheum 58:964-75. 2008
    ..To assess the efficacy, safety, and pharmacology of subcutaneous administration of golimumab in patients with active rheumatoid arthritis (RA) despite treatment with methotrexate (MTX)...
  99. ncbi request reprint Early detection of rheumatoid arthritis made easier. Accurate early diagnosis may facilitate treatment decisions
    Eric L Matteson
    Health News 9:12-3. 2003
  100. ncbi request reprint CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis
    Joshua J Michel
    Children s Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Arthritis Rheum 56:43-57. 2007
    ..T cells deficient in CD28 expression have been implicated in the pathogenesis of rheumatoid arthritis (RA). Given that CD28-null T cells are functionally heterogeneous, we undertook this study to screen for novel receptors on these cells...
  101. ncbi request reprint Managing comorbidity risks in rheumatoid arthritis
    Sonja A Dechant
    Curr Opin Rheumatol 16:177-9. 2004

Research Grants1

  1. Genetic Polymorphisms in Rheumatoid Arthritis
    Eric Matteson; Fiscal Year: 2004
    ..The mentorship program proposed in this grant is critical to this long-term goal. ..